clinical-trial
7 stories related to this topic, newest first.
indiatoday.intoday.inTrial Tests Myostatin Inhibitor With Tirzepatide for Lean Mass Retention
A randomized trial examined whether a myostatin inhibitor preserves lean mass during tirzepatide treatment. The study reported 55 percent retention of lean mass compared with placebo.
nbcnews.comBictegravir-Lenacapavir Single Pill Non-Inferior to Complex Regimens in Heavily Treatment-Experienced HIV Patients
A phase-three study found the once-daily bictegravir-lenacapavir combination non-inferior to nine complex regimens. The trial enrolled 557 adults who had taken HIV treatment for an average of 28 years.
New York PostNASA Engineer Receives Double-Lung Transplant for Advanced Lung Cancer
A 61-year-old NASA robotic software developer underwent a double-lung transplant through a clinical trial for patients with advanced lung cancer. The procedure, performed on Thanksgiving Day 2025 at Northwestern Medicine in Chicago, has left her cancer-free and able to breathe wi…
The GuardianOpera Singer Reports Improved Hearing After Double Cochlear Implants
A London opera singer who concealed her deafness for over 30 years underwent double cochlear implants in 2019. She stated the procedure restored her hearing and improved her quality of life. A nationwide trial is now evaluating bilateral implants for adults to potentially expand…
benzinga.comLaw Firm Reminds Nektar Therapeutics Investors of Lead Plaintiff Deadline in Securities Class Action
A law firm has issued a reminder for investors in Nektar Therapeutics who purchased securities during a specified period to file a lead plaintiff motion by May 5, 2026. The class action relates to a clinical trial failure announced in December 2025 that led to a stock price decli…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Pancreatic Cancer Trial
Revolution Medicines announced that its drug daraxonrasib met primary and secondary endpoints in a Phase 3 trial for pancreatic cancer patients whose disease had progressed on prior treatment. The trial showed a median overall survival of 13.2 months for daraxonrasib compared to…
Mark Klimek / Wikimedia (CC BY-SA 2.0)Clinical Trial Demonstrates Base Editing Effectiveness for β-Thalassaemia Treatment
Researchers have applied base editing to treat β-thalassaemia in a clinical setting, reactivating the fetal hemoglobin gene. The trial shows improved gene editing processes that address the blood disorder. This development builds on prior research in gene therapy for hemoglobinop…